Home > Insider Trading > Metabasis Therapeutics Inc > Profile

Metabasis Therapeutics Inc (MBRX)

Market is closed

Get Email Alerts

Profile
Hedge Fund Holdings
Insider Purchases
Insider Sales
Institutional Holdings
13 D/G Filings
News

Get Email Alerts

Sector: Pharmaceutical Preparations

Related Insiders

Ansbert Gadicke, Large Shareholder, 2010-01-29
Michael Steinmetz, Large Shareholder, 2010-01-29
Nicholas Galakatos, Large Shareholder, 2010-01-29

Ansbert Gadicke, Large Shareholder, 2010-01-29
Michael Steinmetz, Large Shareholder, 2010-01-29
Nicholas Galakatos, Large Shareholder, 2010-01-29
Kurt Wheeler, Large Shareholder, 2010-01-29
Mpm Asset Management Investors 2000B Llc, Large Shareholder, 2010-01-29
Mpm Asset Management Ii Lp, Large Shareholder, 2010-01-29
Mpm Asset Management Ii Llc, Large Shareholder, 2010-01-29
Mpm Bioventures Ii Lp, Large Shareholder, 2010-01-29
Mpm Bioventures Ii Qp Lp, Large Shareholder, 2010-01-29
Mpm Bioventures Gmbh & Co Parallel Beteiligungs Kg, Large Shareholder, 2010-01-29
Luke Evnin, Large Shareholder, Director, 2010-01-29

Show All Insiders (11)

News See All

Moleculin Biotech, Inc. (NASDAQ:MBRX) Q1 2024 Earnings Call Transcript

Operator: Hello, and welcome to the Moleculin Biotech first quarter 2024 quarterly update conference call and webcast. A question-and-answer session will follow the formal presentation.

Keep Reading →

May 14th, 2024 - News Transcripts

Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2023 Earnings Call Transcript

Operator: Greetings, welcome to the Moleculin Biotech 2023 Year-End Conference Call and Webcast. [Operator Instructions] Please note, that this conference is being recorded.

Keep Reading →

March 26th, 2024 - News Transcripts

Moleculin Biotech, Inc. (NASDAQ:MBRX) Q3 2023 Earnings Call Transcript

Operator: Greetings, and welcome to the Moleculin Biotech Third Quarter 2023 Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.

Keep Reading →

November 14th, 2023 - News Transcripts

Moleculin Biotech, Inc. (NASDAQ:MBRX) Q2 2023 Earnings Call Transcript

Operator: Hello, and welcome to the Moleculin Biotech Quarterly Update Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.

Keep Reading →

August 13th, 2023 - News Transcripts

Moleculin Biotech, Inc. (NASDAQ:MBRX) Q1 2023 Earnings Call Transcript

Operator: Hello and welcome to the Moleculin Biotech Q1 2023 Quarterly Update Conference Call and Webcast. A question-and-answer session will follow the formal presentation.

Keep Reading →

May 12th, 2023 - News Transcripts

Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2022 Earnings Call Transcript

Operator: Hello and welcome to the Moleculin Biotech Fiscal Year 2022 Quarterly Update Conference Call and Webcast. A question-and-answer session will follow the formal presentation.

Keep Reading →

March 27th, 2023 - News Transcripts

13G Filing: Sabby Capital and Moleculin Biotech Inc (MBRX)

Sabby Healthcare Master Fund, Ltd | 0 | 0 | 0 | 0 | 0 | 0 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO CUSIP No. 60855D101 1. NAME OF REPORTING PERSONS Sabby Volatility Warrant Master Fund, Ltd.

Keep Reading →

January 8th, 2018 - Hedge Funds

Moleculin Biotech Inc (MBRX): Proceed With Caution

Moleculin Biotech Inc (NASDAQ:MBRX), an oncology-focused pharmaceutical firm that just joined public markets in June, is making some waves in the biotech world.

Keep Reading →

July 27th, 2016 - News Stock Analysis

Click here to See All News

Follow Insider Monkey at Twitter

Insider Monkey Quarterly Strategy

+275.3% Insider Monkey Quarterly Strategy

+125.2% Benchmark50% S&P 500 ETF and 50% Russell 2000 ETF

200%

100%

Subscribe Now

Returns since its inception in May 2014 (through May 20, 2024)

Hedge Fund Resource Center